フォロー
Neta Rosenzweig
Neta Rosenzweig
Brigham and Women's Hospital
確認したメール アドレス: BWH.HARVARD.EDU
タイトル
引用先
引用先
Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus
R Shechter, O Miller, G Yovel, N Rosenzweig, A London, J Ruckh, ...
Immunity 38 (3), 555-569, 2013
7372013
Breaking immune tolerance by targeting Foxp3+ regulatory T cells mitigates Alzheimer’s disease pathology
K Baruch, N Rosenzweig, A Kertser, A Deczkowska, AM Sharif, A Spinrad, ...
Nature communications 6 (1), 7967, 2015
4742015
PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease
K Baruch, A Deczkowska, N Rosenzweig, A Tsitsou-Kampeli, AM Sharif, ...
Nature medicine 22 (2), 135-137, 2016
3942016
IFN-γ-dependent activation of the brain’s choroid plexus for CNS immune surveillance and repair
G Kunis, K Baruch, N Rosenzweig, A Kertser, O Miller, T Berkutzki, ...
Brain 136 (11), 3427-3440, 2013
3522013
Mef2C restrains microglial inflammatory response and is lost in brain ageing in an IFN-I-dependent manner
A Deczkowska, O Matcovitch-Natan, A Tsitsou-Kampeli, S Ben-Hamo, ...
Nature communications 8 (1), 717, 2017
2372017
PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model
N Rosenzweig, R Dvir-Szternfeld, A Tsitsou-Kampeli, H Keren-Shaul, ...
Nature communications 10 (1), 465, 2019
1682019
APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints
Z Yin, N Rosenzweig, KL Kleemann, X Zhang, W Brandão, MA Margeta, ...
Nature immunology 24 (11), 1839-1853, 2023
822023
Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
M Eisenbach-Schwartz, K Baruch, N Rosenzweig
US Patent 9,394,365, 2016
502016
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
M Eisenbach-Schwartz, K Baruch, N Rosenzweig
US Patent 9,856,318, 2018
452018
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
M Eisenbach-Schwartz, K Baruch, N Rosenzweig
US Patent 10,214,585, 2019
322019
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
M Eisenbach-Schwartz, K Baruch, N Rosenzweig
US Patent 10,144,778, 2018
322018
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
M Eisenbach-Schwartz, K Baruch, N Rosenzweig
US Patent 10,519,237, 2019
302019
Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease
M Eisenbach-Schwartz, K Baruch, N Rosenzweig
US Patent 9,512,225, 2016
232016
Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease
M Eisenbach-Schwartz, K Baruch, N Rosenzweig
US Patent 9,534,052, 2017
212017
Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease
M Eisenbach-Schwartz, K Baruch, N Rosenzweig
US Patent 9,512,227, 2016
212016
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
M Eisenbach-Schwartz, K Baruch, N Rosenzweig
US Patent 10,618,963, 2020
152020
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
M Eisenbach-Schwartz, K Baruch, N Rosenzweig
US Patent 9,982,051, 2018
112018
Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
M Eisenbach-Schwartz, K Baruch, N Rosenzweig
US Patent 9,982,049, 2018
112018
Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease
M Eisenbach-Schwartz, K Baruch, N Rosenzweig
US Patent 9,982,047, 2018
112018
Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
M Eisenbach-Schwartz, K Baruch, N Rosenzweig
US Patent 9,982,050, 2018
112018
現在システムで処理を実行できません。しばらくしてからもう一度お試しください。
論文 1–20